Circulating tumor DNA analysis as a real-time method f melanoma patients undergoing treatment with immun

DOI: 10.1186/s40425-014-0042-0

Citation Report

#	Article	IF	Citations
1	Revisiting determinants of prognosis in cutaneous melanoma. Cancer, 2015, 121, 4108-4123.	2.0	75
2	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
3	Circulating Cell-Free Tumour DNA in the Management of Cancer. International Journal of Molecular Sciences, 2015, 16, 14122-14142.	1.8	104
4	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific Reports, 2015, 5, 11198.	1.6	150
5	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. Journal of Neuro-Oncology, 2015, 123, 373-383.	1.4	14
6	Immunomodulation: checkpoint blockade etc.: Fig. 1.. Neuro-Oncology, 2015, 17, vii26-vii31.	0.6	26
7	Ovarian cancer treatment: The end of empiricism?. Cancer, 2015, 121, 3203-3211.	2.0	30
8	A Place for BRAFV600E Mutation-specific Immunohistochemistry Alongside Cell-free DNA Mutation Detection in Melanoma. Acta Dermato-Venereologica, 2016, 96, 426-427.	0.6	0
9	Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget, 2016, 7, 48832-48841.	0.8	234
10	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research, 2016, 26, 157-163.	0.6	16
11	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer, 2016, 16, 850.	1.1	22
12	Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research, 2016, 22, 5497-5505.	3.2	118
13	Cell-free circulating tumor DNA in cancer. Chinese Journal of Cancer, 2016, 35, 36.	4.9	119
14	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2016, 22, 5480-5486.	3.2	84
15	Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology. International Journal of Oncology, 2016, 49, 2088-2104.	1.4	4
16	Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Scientific Reports, 2016, 6, 22498.	1.6	96
17	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist, 2016, 21, 84-94.	1.9	20
18	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery, 2016, 6, 286-299.	7.7	208

#	Article	IF	Citations
19	The clinical potential of Enhanced-ice-COLD-PCR. Expert Review of Molecular Diagnostics, 2016, 16, 265-268.	1.5	17
20	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research, 2016, 22, 567-574.	3.2	185
21	Sensitivity of plasma BRAF^{mutant} and NRAS^{mutant} cellâ€free DNA assays to detect metastatic melanoma in patients with low RECIST scores and nonâ€RECIST disease progression. Molecular Oncology, 2016, 10, 157-165.	2.1	63
22	Circulating-tumor DNA as an early detection and diagnostic tool. Current Opinion in Genetics and Development, 2017, 42, 14-21.	1.5	84
23	Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017, 17, 223-238.	12.8	1,786
24	Advances in Circulating Tumor DNA Analysis. Advances in Clinical Chemistry, 2017, 80, 73-153.	1.8	23
26	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Annals of Oncology, 2017, 28, 1996-2001.	0.6	223
27	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine, 2017, 58, 1421-1428.	2.8	209
28	CTCs and ctDNA: Two Tales of a Complex Biology. Cancer Drug Discovery and Development, 2017, , 119-137.	0.2	1
29	Very early response of circulating tumourâ€“derived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonâ€“small cell lung cancer. European Journal of Cancer, 2017, 86, 349-357.	1.3	82
30	Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Scientific Reports, 2017, 7, 14605.	1.6	22
31	Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations. Pharmaceutical Medicine, 2017, 31, 217-233.	1.0	4
32	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98
33	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respiratory Medicine Case Reports, 2017, 22, 31-33.	0.2	6
34	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. Journal of Molecular Diagnostics, 2017, 19, 126-136.	1.2	29
35	SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. Bioinformatics, 2017, 33, 26-34.	1.8	48
36	Metastatic pathways in patients with cutaneous melanoma. Pigment Cell and Melanoma Research, 2017, 30, 13-27.	1.5	38
37	ImmunothÃ©rapie et cancer du poumon : oÃ¹ en sommes-nous ?. Revue Des Maladies Respiratoires Actualites, 2017, 9, 315-324.	0.0	1

#	Article	IF	Citations
38	Concerning the article by Louveauet al â€œClinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitorâ€• ESMO Open, 2017, 2, e000207.	2.0	0
39	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. BioMed Research International, 2017, 2017, 1-8.	0.9	39
40	Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer. Scientific Reports, 2017, 7, 16723.	1.6	39
41	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget, 2017, 8, 78174-78192.	0.8	75
42	Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1363-1374.	0.9	59
43	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	1.5	51
44	Circulating Tumor DNA in Nonâ€“Small-Cell Lung Cancer: A Primer for the Clinician. JCO Precision Oncology, 2017, 1, 1-13.	1.5	11
45	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. Clinical Chemistry, 2018, 64, 830-842.	1.5	50
46	The value of cellâ€free DNA for molecular pathology. Journal of Pathology, 2018, 244, 616-627.	2.1	91
47	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
48	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
49	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 2018, 24, 1872-1880.	3.2	319
50	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clinical and Translational Oncology, 2018, 20, 966-974.	1.2	31
51	Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. Annals of Oncology, 2018, 29, 311-323.	0.6	74
52	Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. Radiation Oncology, 2018, 13, 75.	1.2	10
53	Circulating cell-free DNA for non-invasive cancer management. Cancer Genetics, 2018, 228-229, 169-179.	0.2	71
54	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. Pathobiology, 2018, 85, 146-154.	1.9	33
55	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	3.3	46

#	Article	IF	Citations
56	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Melanoma Research, 2018, 28, 65-70.	0.6	18
57	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	1.5	25
58	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Frontiers in Oncology, 2018, 8, 610.	1.3	6
59	Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget, 2018, 9, 36238-36249.	0.8	28
60	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Medicine, 2018, 16, 166.	2.3	181
61	Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy, 2018, 10, 1023-1025.	1.0	11
62	Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. Journal of Diabetes and Metabolic Disorders, 2018, 17, 19-30.	0.8	13
63	In Vitro Cell-free DNA Quantification: A Novel Method to Accurately Quantify Cell Survival after Irradiation. Radiation Research, 2018, 190, 22.	0.7	1
64	Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. Clinical Chemistry, 2018, 64, 1338-1346.	1.5	9
65	Therapeutic vaccination with 4â€“1BB co-stimulation eradicates mouse acute myeloid leukemia. Oncolmmunology, 2018, 7, e1486952.	2.1	6
66	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology, 2018, 15, 639-650.	12.5	152
67	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clinical Cancer Research, 2018, 24, 6212-6222.	3.2	168
68	From validity to clinical utility: the influence of circulating tumor <scp>DNA</scp> on melanoma patient management in a realâ€world setting. Molecular Oncology, 2018, 12, 1661-1672.	2.1	32
69	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer, 2018, 17, 129.	7.9	536
70	How liquid biopsies can change clinical practice in oncology. Annals of Oncology, 2019, 30, 1580-1590.	0.6	231
71	Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma. Annals of Thoracic Surgery, 2019, 108, 343-349.	0.7	36
72	Serial ultraâ€deep sequencing of circulating tumor DNA reveals the clonal evolution in nonâ€small cell lung cancer patients treated with antiâ€PD1 immunotherapy. Cancer Medicine, 2019, 8, 7669-7678.	1.3	27
73	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. Pharmacogenomics, 2019, 20, 1259-1270.	0.6	6

#	Article	IF	Citations
74	The current status of the clinical utility of liquid biopsies in cancer. Expert Review of Molecular Diagnostics, 2019, 19, 1031-1041.	1.5	27
75	Clinical significance of plasma free DNA in patients with non-small cell lung cancer. Journal of International Medical Research, 2019, 47, 5593-5600.	0.4	1
76	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459.	0.6	146
77	Immune checkpoint inhibition for the treatment of mesothelioma. Expert Opinion on Biological Therapy, 2019, 19, 697-706.	1.4	18
78	The emerging role of cell-free DNA as a molecular marker for cancer management. Biomolecular Detection and Quantification, 2019, 17, 100087.	7.0	375
79	Cellâ€free tumour <scp>DNA</scp> testing for early detection of cancer â€“ a potential future tool. Journal of Internal Medicine, 2019, 286, 118-136.	2.7	50
80	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	1.0	17
81	Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. Apmis, 2019, 127, 329-336.	0.9	16
82	Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates. , 0, , .		0
83	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 820-828.	1.9	87
84	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precision Oncology, 2019, 3, 1-10.	1.5	25
85	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research, 2019, 25, 7024-7034.	3.2	104
86	Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. Head and Neck, 2019, 41, 1351-1358.	0.9	22
87	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 2019, 14, 16-24.	0.5	100
88	Alignment-free clustering of UMI tagged DNA molecules. Bioinformatics, 2019, 35, 1829-1836.	1.8	23
89	Advances in Porous Siliconâ€“Based Nanomaterials for Diagnostic and Therapeutic Applications. Advanced Therapeutics, 2019, 2, 1800095.	1.6	92
90	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
91	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clinical Cancer Research, 2019, 25, 1494-1504.	3.2	45

#	Article	IF	Citations
92	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. Cancers, 2020, 12, 2914.	1.7	26
93	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
94	Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes. Pediatric Blood and Cancer, 2020, 67, e28758.	0.8	6
95	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	3.2	41
96	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 2020, 12, 3486.	1.7	10
97	Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2416-2422.	1.1	17
98	Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis. Acta OncolÃ³gica, 2020, 59, 1388-1392.	0.8	0
99	10-Plex Digital Polymerase Chain Reaction with Four-Color Melting Curve Analysis for Simultaneous KRAS and BRAF Genotyping. Analytical Chemistry, 2020, 92, 11705-11713.	3.2	29
100	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery, 2020, 10, 1842-1853.	7.7	179
101	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs, 2020, 34, 463-476.	2.2	49
102	Acquired Resistance to Immune Checkpoint Blockade Therapies. Cancers, 2020, 12, 1161.	1.7	9
103	Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients. Cancer Biomarkers, 2020, 28, 111-119.	0.8	9
104	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. Cancers, 2020, 12, 1414.	1.7	15
105	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
106	Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Nonâ€Small Cell Lung Cancer. Advanced Science, 2020, 7, 1903410.	5.6	30
107	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Frontiers in Molecular Biosciences, 2020, 7, 113.	1.6	52
108	Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	1.4	31
109	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. Tumori, 2020, 106, 241-248.	0.6	13

#	Article	IF	Citations
110	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1799-1807.	1.4	10
111	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine, 2020, 9, 286.	1.0	50
112	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. Cancers, 2020, 12, 960.	1.7	25
113	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 157, 103187.	2.0	17
114	Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer. Oncologie, 2021, 23, 335-350.	0.2	1
115	Dense array of floating water droplets aligned to an assembly of tubular wells. Japanese Journal of Applied Physics, 2021, 60, 037002.	0.8	1
117	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. Cancers, 2021, 13, 1227.	1.7	9
118	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
119	Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers, 2021, 13, 1826.	1.7	9
120	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101681.	0.7	4
121	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
122	The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis. Translational Oncology, 2021, 14, 101072.	1.7	8
123	Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy. Critical Reviews in Oncology/Hematology, 2021, 162, 103340.	2.0	26
124	Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncology, 2021, 17, 2683-2692.	1.1	2
125	Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. Future Oncology, 2021, 17, 4115-4129.	1.1	4
126	The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 671874.	1.3	14
127	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 678409.	1.6	15
128	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers, 2021, 13, 3600.	1.7	37

#	Article	IF	Citations
129	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biology and Therapy, 2021, 22, 455-464.	1.5	6
130	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers, 2021, 13, 4280.	1.7	16
131	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer Biomarkers, 2021, 32, 1-13.	0.8	2
132	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
133	Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer Science, 2021, 112, 4748-4757.	1.7	9
134	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. International Journal of Molecular Sciences, 2021, 22, 9714.	1.8	20
135	Hyperprogression: A novel response pattern under immunotherapy. Clinical and Translational Medicine, 2020, 10, e167.	1.7	22
136	A field guide for cancer diagnostics using cellâ€free DNA: From principles to practice and clinical applications. Genes Chromosomes and Cancer, 2018, 57, 123-139.	1.5	155
137	Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. Methods in Molecular Biology, 2020, 2055, 155-180.	0.4	7
138	Dynamic Treatment Stratification Using ctDNA. Recent Results in Cancer Research, 2020, 215, 263-273.	1.8	9
139	Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA. Bioscience Reports, 2020, 40, .	1.1	9
140	Clinical correlates for immune checkpoint therapy: significance for CNS malignancies. Neuro-Oncology Advances, 2021, 3, vdaa161.	0.4	11
141	Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report. American Journal of Case Reports, 2017, 18, 26-32.	0.3	7
142	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	1.4	95
143	Role of liquid biopsy for thoracic cancers immunotherapy. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 183-199.	0.5	5
144	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. Journal of Cancer Therapy, 2016, 07, 573-585.	0.1	1
145	Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification. British Journal of Pharmacy, 2016, 1, .	0.1	0
146	Novel Methods to Overcome Acquired Resistance to Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 97-129.	0.1	0

#	Article	IF	Citations
147	Pseudoprogression in lung cancer: a case report. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	0
148	Improved EGFR mutation detection sensitivity after enrichment by Cas9/sgRNA digestion and PCR amplification. Acta Biochimica Et Biophysica Sinica, 2020, 52, 1316-1324.	0.9	4
149	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. American Journal of Cancer Research, 2018, 8, 1947-1956.	1.4	6
150	How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. American Journal of Cancer Research, 2019, 9, 1546-1553.	1.4	37
151	Detection of circulating tumor cell DNA for monitoring advanced gastric cancer. International Journal of Clinical and Experimental Pathology, 2020, 13, 203-211.	0.5	4
152	Machine Learning Analysis of Immune Cells for Diagnosis and Prognosis of Cutaneous Melanoma. Journal of Oncology, 2022, 2022, 1-15.	0.6	2
153	Circulating Tumour DNA in Melanomaâ€"Clinic Ready?. Current Oncology Reports, 2022, 24, 363-373.	1.8	10
154	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging, 2022, 22, 11.	1.2	2
155	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open, 2022, 12, e055821.	0.8	23
156	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Molecular Cancer, 2022, 21, 86.	7.9	72
157	Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives. Current Treatment Options in Oncology, 2022, 23, 562-577.	1.3	8
158	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	2.2	15
159	Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitorsâ€™ therapeutic outcomes for non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2022, , .	1.2	0
160	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Frontiers in Oncology, 0, 12, .	1.3	27
161	Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions. International Immunopharmacology, 2022, 111, 109173.	1.7	3
164	Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Frontiers in Oncology, 0, 12, .	1.3	4
165	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022, 13, .	5.8	2
166	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24

#	Article	IF	Citations
167	Circulating Tumour DNA: A Promising Cancer Biomarker. , 2023, , 100-114.		0
168	Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. , 2023, 11, e005854.		8
169	Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. Frontiers in Medicine, 0, 10, .	1.2	2
170	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12